California State Teachers Retirement System Has $1.11 Million Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON)

California State Teachers Retirement System raised its stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 115.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,768 shares of the company's stock after acquiring an additional 20,763 shares during the period. California State Teachers Retirement System owned 0.05% of CG Oncology worth $1,112,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of CG Oncology by 15.3% in the 4th quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company's stock worth $168,096,000 after acquiring an additional 779,730 shares during the period. Barclays PLC increased its stake in shares of CG Oncology by 331.1% in the third quarter. Barclays PLC now owns 90,520 shares of the company's stock valued at $3,416,000 after purchasing an additional 69,523 shares during the period. New York State Common Retirement Fund raised its holdings in shares of CG Oncology by 16.7% during the fourth quarter. New York State Common Retirement Fund now owns 13,996 shares of the company's stock valued at $401,000 after buying an additional 2,000 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of CG Oncology by 45.3% during the fourth quarter. Wells Fargo & Company MN now owns 28,234 shares of the company's stock valued at $810,000 after buying an additional 8,803 shares during the last quarter. Finally, Swiss National Bank boosted its position in shares of CG Oncology by 144.2% during the fourth quarter. Swiss National Bank now owns 79,600 shares of the company's stock worth $2,283,000 after buying an additional 47,000 shares during the period. 26.56% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CGON. Morgan Stanley decreased their price target on CG Oncology from $55.00 to $52.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Scotiabank started coverage on CG Oncology in a report on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $75.00 target price on shares of CG Oncology in a report on Monday, April 28th. Royal Bank of Canada lifted their price target on CG Oncology from $66.00 to $68.00 and gave the company an "outperform" rating in a report on Tuesday, April 29th. Finally, HC Wainwright reiterated a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Monday, April 28th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $58.22.

CG Oncology Stock Performance

Shares of NASDAQ:CGON traded up $0.48 during midday trading on Tuesday, hitting $27.48. The company's stock had a trading volume of 812,994 shares, compared to its average volume of 831,741. The stock's 50 day simple moving average is $23.28 and its 200 day simple moving average is $26.99. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -18.20 and a beta of 0.86. CG Oncology, Inc. has a fifty-two week low of $14.80 and a fifty-two week high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.09). The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.53 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. As a group, analysts anticipate that CG Oncology, Inc. will post -1.31 EPS for the current year.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $30.76, for a total value of $30,760.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 7.40% of the company's stock.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.